Philip L. McCarthy, M answer .D., Kouros Owzar, Ph.D., Craig C. Hofmeister, M.D., David D. Hurd, M.D., Hani Hassoun, M.D., Paul G. Richardson, M.D., Sergio Giralt, M.D., Edward A. Stadtmauer, M.D., Daniel J. Weisdorf, M.D., Ravi Vij, M.D., Jan S. Moreb, M.D., Natalie Scott Callander, M.D., Koen Van Besien, M.D., Teresa Gentile, M.D., Ph.D., Luis Isola, M.D., Richard T. Maziarz, M.D., Don A. Gabriel, M.D., Ph.D., Asad Bashey, M.D., Ph.D., Heather Landau, M.D., Thomas Martin, M.D., Muzaffar H. Qazilbash, M.D., Denise Levitan, M.D., Brian McClune, M.D., Robert Schlossman, M.D., Vera Hars, M.S., John Postiglione, B.A., Chen Jiang, Ph.D., Elizabeth Bennett, B.H.E., Susan Barry, B.A., Linda Bressler, Pharm.D., Michael Kelly, M.A., Michele Seiler, M.S., Cara Rosenbaum, M.D., Parameswaran Hari, M.D., Marcelo C.

Ladies who received antiretroviral medications other than zidovudine during labor were excluded. All mothers provided written educated consent. Infants were eligible for enrollment if indeed they were no more than 48 hours old, acquired a gestational age of at least 32 weeks, weighed at least 1.5 kg, had no life-threatening conditions, and could actually take oral medication. Receipt of oral zidovudine before research entry was permitted; infants who received various other antiretroviral drugs were excluded. Enrollment occurred at 17 sites in Brazil, South Africa, Argentina, and the United States. The study was approved by regional and collaborating institutional review boards and was examined annually by a data and protection monitoring board.